As a critical mediator modulating the pro-inflammatory signaling pathway, pharmacological inhibition, genetic deletion, or degradation using the proteolysis targeting chimera (PROTAC) of RIPK2 might be beneficial in reducing inflammation in diseases such as ischemic stroke, inflammatory bowel disease, and rheumatoid arthritis. This evidence concerns the gene RIPK2 and ischemic stroke.